Shots:

• The company reported 2yrs. & 1 yrs. results from P-III KITE & KINGFISHER studies evaluating Beovu (6mg- q4w) vs aflibercept (2mg) in 926 patients with DME across 36 countries
• The results showed non-inferiority to aflibercept in a change in BCVA from baseline @100wks. in KITE & 52wks. in KINGFISHER studies. The therapy also demonstrated superior reductions in CSFT & number of eyes with IRF/SRF & was well-tolerated in both studies
• The company has submitted the applications to FDA and the EMA for Beovu to treat DME and plans to submit applications in other regulatory bodies. The 2yrs. results from the P-III KESTREL trial are expected in Q4'21

  Ref: Novartis | Image: Novartis